PhoreMost Ltd., a company at the forefront of targeted protein degradation (TPD) therapies for oncology and inflammation, recently announced a significant advancement with the publication of a study in BioRxiv. This paper details the capabilities of their proprietary GlueSEEKER platform, a high-throughput technology poised to revolutionize the discovery and development of molecular glue degraders.

Traditionally, the discovery of molecular glues—small molecules that induce the degradation of specific target proteins—has been largely serendipitous. GlueSEEKER, however, introduces a systematic and rational approach. The platform achieves this by engineering effector proteins, such as E3 ligases, at scale. This engineering expands the surface landscapes of these proteins, thereby triggering the induced degradation of targeted proteins.

The published study, titled “Systematic molecular glue drug discovery with a high-throughput effector protein remodeling platform,” provides a comprehensive look at GlueSEEKER. It outlines how the platform generates a high-resolution understanding of the precise physical and chemical requirements needed for effective molecular glue development. By integrating quantitative high-throughput biological data with the latest advancements in computational small molecule drug discovery, GlueSEEKER provides the essential "blueprints" for designing these novel therapeutics.

This innovative methodology has the potential to significantly accelerate drug development programs across a broad range of therapeutic areas. By enabling the rational design of molecular glues from virtually any E3 ligase or target, PhoreMost aims to move beyond chance discoveries and usher in a new era of targeted protein degradation therapies.